miR‑181a‑5p inhibits the proliferation and invasion of drug‑resistant glioblastoma cells by targeting F‑box protein 11 expression Corrigendum in /10.3892/ol.2025.14965

Wen,Xueyan; Li,Songrong; Guo,Mengchan; Liao,Hongzhan; Chen,Yongmin; Kuang,Xi; Liao,Xiaoping; Ma,Lin; Li,Qifu

doi:10.3892/ol.2020.12098

November-2020 Volume 20 Issue 5

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

November-2020 Volume 20 Issue 5

Full Size Image

Article Open Access

miR‑181a‑5p inhibits the proliferation and invasion of drug‑resistant glioblastoma cells by targeting F‑box protein 11 expression

Corrigendum in: /10.3892/ol.2025.14965

Authors:
- Xueyan Wen
- Songrong Li
- Mengchan Guo
- Hongzhan Liao
- Yongmin Chen
- Xi Kuang
- Xiaoping Liao
- Lin Ma
- Qifu Li
View Affiliations / Copyright

Affiliations: Department of Neurology, The First Affiliated Hospital of Hainan Medical University, Haikou, Hainan 570102, P.R. China

Copyright: © Wen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Article Number: 235
|
Published online on: September 14, 2020

https://doi.org/10.3892/ol.2020.12098
Expand metrics +

Abstract

Glioblastoma (GBM) is the most common malignant primary tumor in the human central nervous system. The present study aimed to explore the molecular mechanism by which microRNA (miR)‑181a‑5p targets the F‑box protein 11 (FBXO11) in glioma cells to inhibit cell proliferation and invasion. Reverse transcription‑quantitative (RT‑q)PCR was performed to detect the expression levels of miR‑181a‑5p in U251TR cells, U251 cells, primary GBM tissues and relapsed GBM tissues in order to determine the association between miR‑181a‑5p and the chemoresistance of GBM cells. The expression levels of miR‑181a‑5p in GBM cells were modulated via transfecting miR‑181a‑5p mimics and inhibitors. Cell Counting Kit‑8 assays were undertaken to assess the effects of miR‑181a‑5p on drug sensitivity and proliferation of GBM cells. Wound healing assays were performed to examine the effects of miR‑181a‑5p on the migratory ability of GBM cells. Furthermore, the effects of miR‑181a‑5p on the invasive ability of GBM cells were analyzed using an in vitro invasion assay. Flow cytometry analysis was carried out to determine whether overexpression of miR‑181a‑5p can promote the apoptotic rate of GBM cells. RT‑qPCR and western blotting were employed to detect the effects of miR‑181a‑5p on mRNA and protein expression of FBX011. miR‑181a‑5p exhibited low expression in resistant GBM cell lines and recurrent tumor tissues. Dual‑luciferase reporter assays were utilized to detect luciferase activity to verify the targeted regulatory association between miR‑181a‑5p and FBXO11. Upregulation of miR‑181a‑5p promoted the sensitivity of GBM cells to temozolomide (TMZ), increased the apoptotic rate of GBM cells and significantly inhibited the invasive and migratory capacities of GBM cells. In drug‑resistant glioma cells, compared with the miR‑negative control group and the blank group, the expression of miR‑181a‑5p was significantly upregulated (P<0.01), while the expression of FBXO11 protein was downregulated. miR‑181a‑5p increased the sensitivity of GBM cells to TMZ. miR‑181a‑5p significantly inhibited the migratory and invasive capacities of GBM cells. miR‑181a‑5p may become a novel effective target for the treatment of GBM. The results of dual‑luciferase reporter assays indicated that miR‑181a‑5p could target the 3'‑untranslated region of FBXO11. The underlying mechanism may be targeted inhibition of FBXO11 gene expression, or may be associated with apoptosis.

View Figures

View References

1	Strom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, Wolinsky Y, Kruchko C and Barnholtz-Sloan J: CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol. 16 (Suppl 4):iv1–iv63. 2014. View Article : Google Scholar : PubMed/NCBI
2	Bradley CA: Glioblastoma: Stem cells-masters of their fates. Nat Rev Cancer. 17:574–575. 2017. View Article : Google Scholar
3	McCarthy DJ, Komotar RJ, Starke RM and Connolly ES: Randomized trial for short-term radiation therapy with temozolomide in elderly patients with glioblastoma. Neurosurgery. 81:N21–N23. 2017. View Article : Google Scholar : PubMed/NCBI
4	Garros-Regulez L, Aldaz P, Arrizabalaga O, Moncho-Amor V, Carrasco-Garcia E, Manterola L, Moreno-Cugnon L, Barrena C, Villanua J, Ruiz I, et al: mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance. Expert Opin Ther Targets. 20:393–405. 2016. View Article : Google Scholar : PubMed/NCBI
5	Slattery ML, Lee FY, Pellatt AJ, Mullany E, Stevens JR, Samowitz WS, Wolff RK and Herrick JS: Infrequently expressed miRNAs in colorectal cancer tissue and tumor molecular phenotype. Mod Pathol. 31:2092018. View Article : Google Scholar : PubMed/NCBI
6	Irani S: miRNAs signature in head and neck squamous cell carcinoma metastasis: A literature review. J Dent (Shiraz). 17:71–83. 2016.PubMed/NCBI
7	Liu YS, Lin HY, Lai SW, Huang CY, Huang BR, Chen PY, Wei KC and Lu DY: miR-181b modulates EGFR-dependent VCAM-1 expression and monocyte adhesion in glioblastoma. Oncogene. 36:5006–5022. 2017. View Article : Google Scholar : PubMed/NCBI
8	Skaar JR, Pagan JK and Pagano M: SnapShot: F box proteins I. Cell. 137:1160–1160.e1. 2009. View Article : Google Scholar : PubMed/NCBI
9	Wu ZH and Pfeffer LM: MicroRNA regulation of F-box proteins and its role in cancer. Semin Cancer Biol. 36:80–87. 2016. View Article : Google Scholar : PubMed/NCBI
10	Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
11	Bai Y, Liao H, Liu T, Zeng X, Xiao F, Luo L, Guo H and Guo L: miR-296-3p regulates cell growth and multi-drug resistance of human glioblastoma by targeting ether-à-go-go (EAG1). Eur J Cancer. 49:710–724. 2013. View Article : Google Scholar : PubMed/NCBI
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
13	Wick W, Gorlia T, Bendszus M, Taphoorn M, Sahm F, Harting I, Brandes AA, Taal W, Domont J, Idbaih A, et al: Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med. 377:1954–1963. 2017. View Article : Google Scholar : PubMed/NCBI
14	Cavaliere R, Wen PY and Schiff D: Novel therapies for malignant gliomas. Neurol Clin. 25:1141–1171. 2007. View Article : Google Scholar : PubMed/NCBI
15	Chrastina J, Novak Z, Brazdil M and Hermanova M: Glioblastoma multiforme in a patient with isolated hemimegalencephaly. J Neurol Surg Rep. 76:e160–e163. 2015. View Article : Google Scholar : PubMed/NCBI
16	Ding Z, Roos A, Kloss J, Dhruv H, Peng S, Pirrotte P, Eschbacher JM, Tran NL and Loftus JC: A novel signaling complex between TROY and EGFR mediates glioblastoma cell invasion. Mol Cancer Res. 16:322–332. 2018. View Article : Google Scholar : PubMed/NCBI
17	Moinuddin FM, Hirano H, Shinsato Y, Higa N, Arita K and Furukawa T: ATP7B expression in human glioblastoma is related to temozolomide resistance. Oncol Lett. 14:7777–7782. 2017.PubMed/NCBI
18	Guo G, Gong K, Ali S, Ali N, Shallwani S, Hatanpaa KJ, Pan E, Mickey B, Burma S, Wang DH, et al: A TNF-JNK-Axl-ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma. Nat Neurosci. 20:1074–1084. 2017. View Article : Google Scholar : PubMed/NCBI
19	Hochhauser D, Glynne-Jones R, Potter V, Grávalos C, Doyle TJ, Pathiraja K, Zhang Q, Zhang L and Sausville EA: A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter. Mol Cancer Ther. 12:809–818. 2013. View Article : Google Scholar : PubMed/NCBI
20	Bocangel DB, Finkelstein S, Schold SC, Bhakat KK, Mitra S and Kokkinakis DM: Multifaceted resistance of gliomas to temozolomide. Clin Cancer Res. 8:2725–2734. 2002.PubMed/NCBI
21	Thomas AA, Brennan CW, DeAngelis LM and Omuro AM: Emerging therapies for glioblastoma. JAMA Neurol. 71:1437–1444. 2014. View Article : Google Scholar : PubMed/NCBI
22	Fornari F, Pollutri D, Patrizi C, La Bella T, Marinelli S, Gardini AC, Marisi G, Toaldo MB, Baglioni M, Salvatore V, et al: In hepatocellular carcinoma miR-221 modulates sorafenib resistance through inhibition of caspase-3-mediated apoptosis. Clin Cancer Res. 23:3953–3965. 2017. View Article : Google Scholar : PubMed/NCBI
23	Rodriguez-Barrueco R, Nekritz EA, Bertucci F, Yu J, Sanchez-Garcia F, Zeleke TZ, Gorbatenko A, Birnbaum D, Ezhkova E, Cordon-Cardo C, et al: miR-424(322)/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy. Genes Dev. 31:553–566. 2017. View Article : Google Scholar : PubMed/NCBI
24	Carta A, Chetcuti R and Ayers D: An introspective update on the influence of miRNAs in breast carcinoma and neuroblastoma chemoresistance. Genet Res Int. 2014:7430502014.PubMed/NCBI
25	Shahar T, Granit A, Zrihan D, Canello T, Charbit H, Einstein O, Rozovski U, Elgavish S, Ram Z, Siegal T and Lavon I: Expression level of miRNAs on chromosome 14q32.31 region correlates with tumor aggressiveness and survival of glioblastoma patients. J Neurooncol. 130:413–422. 2016. View Article : Google Scholar : PubMed/NCBI
26	López-Ochoa S, Ramírez-García M, Castro-Sierra E and Arenas-Huertero F: Analysis of chromosome 17 miRNAs and their importance in medulloblastomas. Biomed Res Int. 2015:7175092015. View Article : Google Scholar : PubMed/NCBI
27	Ying W, Riopel M, Bandyopadhyay G, Dong Y, Birmingham A, Seo JB, Ofrecio JM, Wollam J, Hernandez-Carretero A, Fu W, et al: Adipose tissue macrophage-derived exosomal miRNAs can modulate in vivo and in vitro insulin sensitivity. Cell. 171:372–384.e12. 2017. View Article : Google Scholar : PubMed/NCBI
28	Piwecka M, Rolle K, Belter A, Barciszewska AM, Żywicki M, Michalak M, Nowak S, Naskręt-Barciszewska MZ and Barciszewski J: Comprehensive analysis of microRNA expression profile in malignant glioma tissues. Mol Oncol. 9:1324–1340. 2015. View Article : Google Scholar : PubMed/NCBI
29	Chen G, Zhu W, Shi D, Lv L, Zhang C, Liu P and Hu W: MicroRNA-181a sensitizes human malignant glioma U87MG cells to radiation by targeting Bcl-2. Oncol Rep. 23:997–1003. 2010.PubMed/NCBI
30	Wilhelm I and Krizbai IA: In vitro models of the blood-brain barrier for the study of drug delivery to the brain. Mol Pharm. 11:1949–1963. 2014. View Article : Google Scholar : PubMed/NCBI